Clinical trials of TN-depletion have been developed for recipients of PBSC grafts. Promising results of the first of these studies have been published in the Journal of Clinical Investigation.  A new phase I trial of HA-1 TCR-engineered T cell immunotherapy is now open and treating patients with relapse of leukemia after HCT. Ultimately, we plan to bring together the graft engineering for GVHD prevention and T cell immunotherapy and vaccination into a comprehensive treatment approach for patients with high-risk hematologic malignancies. Ongoing trials, open to patients, include:

A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD